Sunshine Biopharma Inc (NASDAQ:SBFM) — Market Cap & Net Worth
Market Cap & Net Worth: Sunshine Biopharma Inc (SBFM)
Sunshine Biopharma Inc (NASDAQ:SBFM) has a market capitalization of $5.05 Million ($5.05 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28557 globally and #5797 in its home market, demonstrating a -7.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sunshine Biopharma Inc's stock price $2.12 by its total outstanding shares 4905945 (4.91 Million). Review how much debt does Sunshine Biopharma Inc carry to assess the company's total debt and financial obligations.
Sunshine Biopharma Inc Market Cap History: 2015 to 2026
Sunshine Biopharma Inc's market capitalization history from 2015 to 2026. Data shows change from $4.91 Trillion to $10.40 Million (-70.61% CAGR).
Index Memberships
Sunshine Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #839 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2677 of 3165 |
Weight: Sunshine Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sunshine Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sunshine Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.17x
Sunshine Biopharma Inc's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $627.96 Billion | $447.20K | -$2.16 Million | 1404206.08x | N/A |
| 2019 | $17.66 Billion | $21.12K | -$1.66 Million | 836201.03x | N/A |
| 2020 | $30.81 Billion | $71.41K | -$2.78 Million | 431442.86x | N/A |
| 2021 | $114.70 Billion | $228.43K | -$12.44 Million | 502136.33x | N/A |
| 2022 | $6.28 Billion | $4.35 Million | -$26.74 Million | 1445.05x | N/A |
| 2023 | $2.66 Billion | $24.09 Million | -$4.51 Million | 110.57x | N/A |
| 2024 | $14.72 Million | $34.87 Million | -$5.13 Million | 0.42x | N/A |
| 2025 | $6.03 Million | $36.31 Million | -$5.98 Million | 0.17x | N/A |
Competitor Companies of SBFM by Market Capitalization
Companies near Sunshine Biopharma Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Sunshine Biopharma Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Sunshine Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sunshine Biopharma Inc's market cap moved from $4.91 Trillion to $ 10.40 Million, with a yearly change of -70.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.40 Million | +72.36% |
| 2025 | $6.03 Million | -59.00% |
| 2024 | $14.72 Million | -99.45% |
| 2023 | $2.66 Billion | -57.58% |
| 2022 | $6.28 Billion | -94.53% |
| 2021 | $114.70 Billion | +272.29% |
| 2020 | $30.81 Billion | +74.44% |
| 2019 | $17.66 Billion | -97.19% |
| 2018 | $627.96 Billion | -87.20% |
| 2017 | $4.91 Trillion | +56.25% |
| 2016 | $3.14 Trillion | -36.00% |
| 2015 | $4.91 Trillion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Sunshine Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.05 Million USD |
| MoneyControl | $5.05 Million USD |
| MarketWatch | $5.05 Million USD |
| marketcap.company | $5.05 Million USD |
| Reuters | $5.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more